https://www.selleckchem.com/products/mycro-3.html Among the 100 IBC differentially expressed proteins, 37 were found to be specific to this type of cancer only. Additionally, four proteins were specifically expressed in DCIS and four in fibroadenoma. Compared to corresponding adjacent tissues and normal breast tissues, 18 step-changing proteins were differentially expressed in IBC, 14 in DCIS, and 13 in fibroadenoma, respectively. Compared to DCIS and normal breast tissues, 65 proteins were differentially expressed in IBC with growing levels of malignancy. The identified potential protein biomarkers may be used as diagnostic and/or therapeutic targets in breast tumors. The identified potential protein biomarkers may be used as diagnostic and/or therapeutic targets in breast tumors.Esophageal squamous cell carcinoma (ESCC) is a deadly disease with a low 5-year survival rate. Anti-epidermal growth factor receptor (EGFR) therapy has been widely used in the treatment of malignancies, and chemotherapy regimens that include nimotuzumab have been confirmed to have satisfactory efficacy among esophageal carcinoma (EC) patients. However, a subpopulation of patients may develop resistance to nimotuzumab. Here, we report an advanced ESCC patient who experienced hyperprogressive disease induced by immune checkpoint inhibitors and was then treated with a chemotherapy regimen containing nimotuzumab. NGS examination of this patient demonstrated that PIK3CA mutation and a RICTOR amplification might participate in primary and acquired resistance to nimotuzumab, respectively, via the PI3K/AKT/mTOR signaling pathway. Pretreatment prediction of the response to neoadjuvant chemoradiotherapy (NCRT) helps to determine the subsequent plans for the patients with locally advanced rectal cancer (LARC). If the good responders (GR) and non-good responders (non-GR) can be accurately predicted, they can choose to intensify the neoadjuvant chemoradiotherapy to decrease the risk of tumor progressio